Scailyte, a single-cell biomarker discovery company and Sirona Dx, a leader in multiomic single-cell analytical services, announce a strategic partnership to accelerate the development of Advanced Therapies. The companies will create a powerful biomarker discovery engine, leveraging Sirona Dx technical and laboratory workflow solutions in combination with Scailyte’s AI-driven data analytics platform ScaiVision™ to serve Biopharma and Biotech. The joint platform will enable discovery and validation of ultra-sensitive biomarkers thanks to Sirona Dx leading technical capabilities in single-cell analysis, and the ability of ScaiVision™ to detect complex molecular signatures in biological samples.
The combined workflow will focus on applications within oncology and immunology, including qualification and stratification of patients for clinical trials, analysis of clinical trial results on a deep cellular level or and to advance efficacy and manufacturing processes during CGT development.
The first wave of projects with pharmaceutical and diagnostic companies, will begin in Q2-2022.
“We are truly excited to partner with Sirona Dx. Precision medicine in Immuno-Oncology is still a challenge today, which requires full mastery and exploitation of the most advanced multi-omics approaches, including single-cell technologies and analytics. With our combined expertise in single-cell technologies applied to translational science, AI and biomarker discovery, we will provide powerful solutions to our partners to advance the development of immunotherapies“ said Corinne Solier, COO at Scailyte AG.
Sirona Dx are original pioneers of single-cell and spatial biology, having launched ultra-high parameter, multiplexed single-cell services to biopharma in 2018. Their innovative, technology-agnostic service capabilities contributed to their selection as a Top 10 CRO of 2021 by Medhealth Outlook.
“We are thrilled to announce this strategic partnership with Scailyte” said Andrew Brown, Ph.D. Chief Commercial Officer at Sirona Dx. “Scailyte have developed an incredibly powerful, AI-driven analytical platform which can successfully tease out the most informative biomarker signatures from complex, single-cell, multiomic data sets. Our combined expertise in single-cell, multiomic assay development, data generation and state of the art analysis, will empower biopharma by providing access to transformative single-cell biomarker capabilities to accelerate their immunotherapy programs.”
About Sirona Dx
Sirona Dx is a technical CRO, founded to accelerate the pace of immunotherapy and targeted therapy development. Bridging silos between diagnostics manufacturers and translational clinical research our laboratory offers specialized high complexity, single-cell proteomics and genomics services supporting pharmaceutical companies with their drug discovery and development programs. Learn more at Sironadx.com.
Scailyte AG is a spin-off of ETH Zurich and combines single-cell technologies, high-quality datasets and machine learning methods to identify disease-specific biomarkers, with a focus on oncology and immunology. Scailyte’s proprietary best-in-class data analysis platform ScaiVision associates multimodal single-cell datasets (RNA-/TCR-/BCR-seq, proteomics, etc) with clinical endpoints, such as disease diagnosis, progression, severity, treatment response, in order to identify ultra-sensitive biomarker signatures. Thanks to the single-cell resolution and AI-driven approach, ScaiVision is the most powerful and cutting-edge approach to precise diagnosis and prediction of therapy response. Scailyte leverages a broad network of top clinicians to identify clinical indications with high unmet clinical needs and collaborates with global pharmaceutical and biotech companies to translate the novel biomarkers into ultra-sensitive companion diagnostics (CDx) or IVD assays.